Shares of bluebird bio Inc (NASDAQ:BLUE) have earned an average recommendation of “Hold” from the twenty-five brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $167.00.

BLUE has been the topic of a number of recent research reports. Leerink Swann reaffirmed an “outperform” rating and set a $162.00 price target (up previously from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. BMO Capital Markets increased their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, October 30th. SunTrust Banks increased their target price on shares of bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Jefferies Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and increased their target price for the company from $130.00 to $211.00 in a research note on Monday, December 11th. Finally, Barclays reissued an “overweight” rating and issued a $209.00 target price (up previously from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th.

bluebird bio (NASDAQ BLUE) traded up $5.70 during trading on Friday, reaching $197.50. 560,400 shares of the company were exchanged, compared to its average volume of 933,790. The stock has a market capitalization of $9,050.00, a P/E ratio of -28.17 and a beta of 2.07. bluebird bio has a 52 week low of $73.95 and a 52 week high of $222.03.

In related news, COO Susanna Gatti High sold 1,282 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $172.15, for a total value of $220,696.30. Following the transaction, the chief operating officer now owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Davidson sold 4,000 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00. The disclosure for this sale can be found here. Insiders sold a total of 200,280 shares of company stock worth $37,818,846 in the last ninety days. 3.90% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of BLUE. Meeder Asset Management Inc. increased its stake in bluebird bio by 2,110.3% in the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares during the period. QS Investors LLC increased its stake in bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the period. NuWave Investment Management LLC purchased a new position in bluebird bio in the 4th quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. increased its stake in bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares during the period. Finally, Biondo Investment Advisors LLC purchased a new position in bluebird bio in the 3rd quarter worth about $203,000.

ILLEGAL ACTIVITY WARNING: “bluebird bio Inc (BLUE) Receives $167.00 Average Price Target from Brokerages” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/02/13/bluebird-bio-inc-blue-receives-167-00-average-price-target-from-brokerages.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.